Key facts
- This page summarizes Radhika Tripuraneni's Form 4 filing for Viridian Therapeutics, Inc.\DE (VRDN).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Aug 2026, 17:34.
Radhika Tripuraneni - 14 Aug 2026 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- VRDN
- Reported as of
- 14 Aug 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Aug 2026, 17:34:08 UTC
- Prior SEC filing
- 05 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Tousignant, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Radhika Tripuraneni filed Form 4 for Viridian Therapeutics, Inc.\DE (VRDN) on 18 Aug 2026.
Change
- Previous filing in this sequence was filed on 05 May 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001761114
Primary reporting owner
Tripuraneni Radhika
- Relationship
- Chief Medical Officer
- Address
- C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 103A, WALTHAM
- Signature
- /s/ Jennifer Tousignant, Attorney-in-fact
- Signature date
- 18 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRDN
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +40,000
- Change %
- Price
- $13.21*
- Shares after
- 40,000
- Date
- 14 Aug 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRDN
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -40,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 14 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $13.21
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option is fully vested.